|
Hemogenyx Pharmaceuticals PLC on Wednesday said the third patient has been successfully treated in an ongoing phase 1 clinical trial for a form of leukaemia. The London-headquartered biopharmaceutical company focused on treatments for blood diseases said the treatment was for adults with relapsed/refractory acute myeloid leukaemia [AML], a type of blood cancer. The trial is of HG-CT-1, the company’s proprietary chimeric antigen receptor t-cell therapy. Notably, original acute myeloid leukaemia cells were not detectable in the patient via standard testing methods, following treatment. ‘The treatment was well tolerated and met the trial’s predefined initial safety criteria. Importantly, early indications of clinical efficacy have been observed. Preliminary assessment shows that original AML cells were not detectable in the patient using standard testing methods. The patient will continue to be monitored in line with the [US] Food & Drug Administration-approved trial protocol to evaluate the achievement of the study’s secondary endpoints described below,’ Hemogenyx said. Hemogenyx Chief Executive Officer & Co-Founder Vladislav Sandler said: ‘The successful treatment of the third patient marks another important milestone for Hemogenyx Pharmaceuticals and for patients battling relapsed or refractory AML. We are encouraged by the favorable safety profile observed to date, together with the early signals of efficacy. These results reinforce the promise of HG-CT-1 as a potential new therapy for one of the most aggressive and intractable forms of leukemia. We remain committed to advancing the clinical development of this therapy to address a critical unmet medical need, while also creating long-term value for our shareholders.’ Hemogenyx shares jumped 21% to 1,494.69 pence each on late Wednesday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
